Construction and Clinical Application of Allogeneic PRP Banks: A Novel Regenerative Medicine Strategy to Overcome Individualized Limitations

doi:10.3969/j.issn.1671-2587.2026.04.002

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2026, Vol. 28 ›› Issue (4): 467-475.DOI: 10.3969/j.issn.1671-2587.2026.04.002

Previous Articles Next Articles

Construction and Clinical Application of Allogeneic PRP Banks: A Novel Regenerative Medicine Strategy to Overcome Individualized Limitations

WANG Wenting, WU Fenyi, DANG E, LIU Tao, YIN Wen

Department of Transfusion Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an 710032

Received:2026-07-07 Online:2026-08-20 Published:2026-08-26

Abstract

Abstract: Platelet-rich plasma (PRP) has demonstrated substantial therapeutic efficacy in tissue repair and regenerative medicine, owing to its abundant reservoir of growth factors. However, the widespread clinical application of autologous PRP is hampered by inherent limitations, including interindividual variability, time-consuming preparation, and donor-site complications that impede its broader adoption. The establishment of a standardized allogeneic PRP (al-PRP) bank, which enables ready-to-use availability and batch-to-batch consistency, represents a pivotal innovative strategy to overcome the clinical barriers associated with autologous PRP. This review systematically elaborates the conceptual framework for constructing a standardized al-PRP bank, covering standardized manufacturing procedures and a whole-chain quality control system. Emphasis is placed on fundamental research and clinical evidence derived from human-derived al-PRP, with an in-depth discussion of its clinical value in regenerative scenarios, including osteoarthritis, chronic non-healing wounds, and tendon and ligament injuries. We analyze the regulatory landscape in China pertaining to cell-based therapies and blood products, addressing compliance pathways, technical bottlenecks, ethical considerations, and industry-wide challenges. This review aims to provide a theoretical foundation and practical reference for the clinical translation, standardized implementation, and industrial-scale development of al-PRP banks.

Key words: Allogeneic platelet-rich plasma, Regenerative medicine, Growth factors, Quality control, Clinical translation

CLC Number:

R318
R457.1

WANG Wenting, WU Fenyi, DANG E, LIU Tao, YIN Wen. Construction and Clinical Application of Allogeneic PRP Banks: A Novel Regenerative Medicine Strategy to Overcome Individualized Limitations[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(4): 467-475.

References

[1] Rath M,Spinnen J,Kuhrt L D,et al.Platelet-rich plasma -A comprehensive review of isolation,activation,and application[J]. Acta Biomater,2025,204:52-75.
[2] Anitua E,Padilla S.Tinkering with blood: optimizing the coagulation system for therapeutic purposes[J]. Bioengineering (Basel),2025,12(12):1301.
[3] Gupta A,Migliorini F,Maffulli N.Management of rotator cuff injuries using allogenic platelet-rich plasma[J]. J Orthop Surg Res,2024,19(1):165.
[4] Gupta A,Aratikatla A,Martin S M.Allogenic platelet-rich plasma for the treatment of adhesive capsulitis[J]. Cureus,2023,15(10):e47491.
[5] Romano V,Bignotti S,Forbice E,et al.Allogeneic solid platelet-rich plasma for persistent epithelial neurotrophic defects: a protocol and pilot study[J]. Cornea,2023, 42(4):498-506.
[6] Tang Y K,Li Y S,Chen H W,et al.Application of cord blood-derived platelet-rich plasma in the treatment of diseases[J]. J Int Med Res,2024,52(7):3000605241263729.
[7] Dohan Ehrenfest D M,Rasmusson L,Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF)[J]. Trends Biotechnol,2009,27(3): 158-167.
[8] 单桂秋, 施琳颖, 李艳辉, 等. 自体富血小板血浆制备技术专家共识[J]. 中国输血杂志,2021,34(7):677-683.
[9] Croisé B,Paré A,Joly A,et al.Optimized centrifugation preparation of the platelet rich plasma: Literature review[J]. J Stomatol Oral Maxillofac Surg,2020,121(2): 150-154.
[10] Giannotti L,Di Chiara Stanca B,Spedicato F,et al. Progress in regenerative medicine: exploring autologous platelet concentrates and their clinical applications[J]. Genes,2023,14(9):1669.
[11] Gagliano C,Foti R,Zeppieri M,et al.Umbilical cord blood platelet lysate eyedrops for the treatment of severe ocular surface disorders in graft vs. host disease patients: clinical study[J]. Life (Basel),2024,14(10):1268.
[12] Jo C H,Roh Y H,Kim J E,et al.Optimizing platelet-rich plasma gel formation by varying time and gravitational forces during centrifugation[J]. J Oral Implantol,2013, 39(5):525-532.
[13] da Silva L Q,Montalvão S A L,Justo-Junior A D S,et al. Platelet-rich plasma lyophilization enables growth factor preservation and functionality when compared with fresh platelet-rich plasma[J]. Regen Med,2018,13(7):775-784.
[14] Saqlain N,Mazher N,Fateen T,et al.Comparison of single and double centrifugation methods for preparation of Platelet-Rich Plasma (PRP)[J]. Pak J Med Sci,2023, 39(3):634-637.
[15] Panero A J,Warrick A E,Nakagawa H,et al.Comparing biologic factor composition of birth tissue-derived allografts and platelet-rich plasma[J]. Cureus,2025,17(8): e90259.
[16] Nakhaei Amroodi M,Mokhtari K,Tabrizian P.Platelet-rich plasma in orthopedics: unraveling cellular mechanisms,therapeutic potential,and limitations[J]. Galen Med J,2025,14:e3883.
[17] Zhang G M,Song Y N,Zhuang T S,et al.Clinical application and research progress of platelet-rich plasma[J]. Hematology,2025,30(1):2549159.
[18] Zhang Z Y,Huang A W,Fan J J,et al.The potential use of allogeneic platelet-rich plasma for large bone defect treatment: immunogenicity and defect healing efficacy[J]. Cell Transplant,2013,22(1):175-187.
[19] Qin H J,Yang H,Wang J,et al.Progress in the clinical application of allogeneic platelet-rich plasma for diabetic foot treatment[J]. Front Endocrinol,2025,16:1694691.
[20] Hassan N H,Ahmad R E,Kamarul T,et al.Allogenic platelet-rich plasma for treating cartilage injury: a systematic review of the evidence on the basic sciences for potential future applications[J]. Cells Tissues Organs,2024,213(4):338-355.
[21] Suelzu C M,Conti V,Khalidy Y,et al.Xenobiotic-free medium guarantees expansion of adipose tissue-derived canine mesenchymal stem cells both in 3D fibrin-based matrices and in 2D plastic surface cultures[J]. Cells,2020, 9(12):2578.
[22] Catarino J,Carvalho P,Santos S,et al.Treatment of canine osteoarthritis with allogeneic platelet-rich plasma: review of five cases[J]. Open Vet J,2020,10(2):226-231.
[23] Van Reusel Y,Broeckx S Y,Carolo A,et al. Composition of allogeneic equine orthobiologics and their repeated intra-articular administrations[J]. Equine Vet J,2026:evj. 70196.
[24] Zhu X H,Zhao L Y,Riva N,et al.Allogeneic platelet-rich plasma for knee osteoarthritis in patients with primary immune thrombocytopenia: A randomized clinical trial[J]. iScience,2024,27(5):109664.
[25] Sánchez M,Guadilla J,Jorquera C,et al.Intra-articular injections of allogeneic platelet-rich plasma from responder patients for the treatment of knee osteoarthritis: a pilot and feasibility clinical trial[J]. CARTILAGE,2025: 19476035251355522.
[26] Caiaffa V,Ippolito F,Abate A,et al.Allogenic platelet concentrates from umbilical cord blood for knee osteoarthritis: preliminary results[J]. Med Glas,2021, 18(1):260-266.
[27] Araya N,Miyatake K,Tsuji K,et al.Intra-articular injection of pure platelet-rich plasma is the most effective treatment for joint pain by modulating synovial inflammation and calcitonin gene-related peptide expression in a rat arthritis model[J]. Am J Sports Med, 2020,48(8):2004-2012.
[28] Huang G S,Peng Y J,Hwang D W,et al.Assessment of the efficacy of intra-articular platelet rich plasma treatment in an ACLT experimental model by dynamic contrast enhancement MRI of knee subchondral bone marrow and MRI T2 measurement of articular cartilage[J]. Osteoarthr Cartil,2021,29(5):718-727.
[29] Del Amo C,Perez-Valle A,Atilano L,et al.Unraveling the signaling secretome of platelet-rich plasma: towards a better understanding of its therapeutic potential in knee osteoarthritis[J]. J Clin Med,2022,11(3):473.
[30] Wang L L,Zhao L T,Shen L W,et al.Comparison of the effects of autologous and allogeneic purified platelet-rich plasma on cartilage damage in a rabbit model of knee osteoarthritis[J]. Front Surg,2022,9:911468.
[31] Giusti S,Cerulli S,Giacinto E,et al.Is umbilical cord-derived platelet-rich plasma a valid alternative to conventional orthobiologics post-knee arthroscopy?[J]. Adv Orthop,2025,2025:8026214.
[32] 巩蜜蜜,汪海宁,吴磊,等. 同种异体富血小板血浆用于慢性难愈性创面的临床研究[J]. 临床输血与检验,2023, 25(3):368-374.
[33] Li Y L,Wang X T,Li Y C,et al.Efficacy and safety of allogeneic platelet-rich plasma in chronic wound treatment: a meta-analysis of randomized controlled trials[J]. Sci Rep,2024,14(1):25209.
[34] He M,Chen T Y,Lv Y H,et al.The role of allogeneic platelet-rich plasma in patients with diabetic foot ulcer: Current perspectives and future challenges[J]. Front Bioeng Biotechnol,2022,10:993436.
[35] 王淑君. 异体富血小板血浆治疗难治性创面的临床及基础研究[D]. 南京:东南大学,2023.
[36] 刘凌,卢黎琦,刘曹毅,等. 同种异体富血小板血浆在创面修复中的应用及展望[J]. 中国输血杂志,2024,37(4):482-490.
[37] Zhu X H,Zhao L Y,Liu A,et al.Efficacy of intra-articular injection of allogeneic platelet-rich plasma for knee osteoarthritis combined with hematologic blood dyscrasias with platelet dysfunction: protocol of a randomized,double-blind,placebo-controlled trial[J]. BMC Musculoskelet Disord,2022,23(1):1095.
[38] Serteyn D,Graide H,Ceusters J,et al.Sequential application of autologous platelet rich plasma and muscle-derived mesenchymal stem cells for acute tendon injuries in horses: early clinical and ultrasonographic outcomes in a randomized,double-blind controlled study[J]. Animals,2026,16(6):940.
[39] Wu W S,Chen L R,Chen K H.Platelet-rich plasma (PRP): molecular mechanisms,actions and clinical applications in human body[J]. Int J Mol Sci,2025,26(21):10804.
[40] Sclafani A P,Azzi J.Platelet preparations for use in facial rejuvenation and wound healing: a critical review of current literature[J]. Aesthetic Plast Surg,2015,39(4): 495-505.
[41] Chatha P K,Pellakuru S R,Botchu R,et al.Orthobiologics: current evidence and what lies beyond the horizon?[J]. Semin Musculoskelet Radiol,2026,30(1): 14-27.
[42] Acebes-Huerta A,Martínez-Botía P,Carbajo-Argüelles G,et al.Characterization of the molecular composition and in vitro regenerative capacity of platelet-based bioproducts and related subfractions[J]. Acta Biomater, 2024,177:132-147.
[43] Mohseni R,Mahdavi Sharif P,Khosravi A,et al. The application of umbilical cord blood-derived platelet gel for skin ulcers associated with chronic graft-versus-host disease in pediatrics: a randomized trial[J]. Transplant Cell Ther,2024,30(7):694.e1-694.e10.
[44] Tomac A A,Coșarcă C M,Trâmbițaș C,et al.Platelet-rich plasma in the management of diabetic foot ulcers (Review)[J]. Biomed Rep,2026,24(6):69.

Construction and Clinical Application of Allogeneic PRP Banks: A Novel Regenerative Medicine Strategy to Overcome Individualized Limitations

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 13

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	WANG Lulu, CHEN Lida, LU Hongkai, LIU Xixi, GUO Weijie, GAO Xin, CAO Yongtong. A Pre-treatment Strategy for Reducing Non-specific Background in Flow Fluorometric PRA Testing [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(4): 539-545.
[2]	MA Yiming, MA Chao, ZHANG Yonggang, LI Xiaofei. Logical Basis and Implementation Pathway for Transfusion Medicine Department-led In-hospital Quality Control of Cell and Gene Therapy [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(3): 312-316.
[3]	Yangtze River Delta Integrated Clinical Blood Transfusion Quality Control, Management Consortium, Shanghai Quality Control Center of Transfusion, The Blood Transfusion Professional Committee of the Shanghai Social Medical Institutions Association, Shanghai Medical Association Transfusion Medicine Branch, Shanghai Medical Association Transfusion Medicine Physicians Branch. Expert Consensus on Checklist-based Quality Management for the Entire Clinical Blood Transfusion Process [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(2): 153-161.
[4]	HAO Mengling, TANG Longhai, JIN Yiming, XIAO Qi, FANG Min. Analysis of Coagulation Factor Ⅷ Levels and Quality Inspection Results in Plasma Products [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 630-637.
[5]	ZHAO Ziyue, HUANG Weihua, CHA Zhanshan. The Prospect of Combined Application of Platelet-rich Plasma and Mesenchymal Stem Cells in Regenerative Medicine [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(3): 420-426.
[6]	Chinese Blood Transfusion Association Clinical Transfusion Management Committee. Chinese Expert Consensus on Preoperative Advanced Autologous Apheresis [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 145-155.
[7]	XIAO Jun, LEI Huifeng, LI Cuiying. The Differential of Growth Factor Expression Profile in Platelet-rich Plasma Lysate and Platelet Gel [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(4): 450-455.
[8]	NIE Zhiyang, ZHAO Xuebin, MA Wanru, et al. Survey and Analysis of National Quality Control Index to Clinical use of Blood in 2020 [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(4): 514-517.
[9]	GUO Gan-ping, JIANG Bi, WANG Xiang-dong, et al. Application of Quality Control Circle Activity in Reducing Emergency Transfusion Waiting Time of Severe Postpartum Hemorrhage Patients during Obstetric Surgery [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(2): 197-201.
[10]	LIANG Ruo-hu, HUANG Yan, DENG Jin-lian, et al. A Feasibility Study on Preparation of Cryoprecipitation with Dewhite Plasma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(2): 134-137.
[11]	DONG Hui-jun, FAN Ren-zhi, ZHOU Hong-yan, et al. Analysis of the On-spot Inspection Results of Specimens from External Quality Assessments in Hospitals of Anhui [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(1): 96-99.
[12]	GU Xiao-zheng,ZHOU Wen-bin,LI Chen-bin,et al.. A Preliminary Assessment of the Self-Made Reference Materials for Detection of Erythrocyte Sedimentation Rate [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2018, 20(4): 402-406.
[13]	SUN You-ling,ZHOU Tao,WAN Sheng-quan,et al. Discussion on Establishment of Quality Control System for Blood Test in Blood [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2018, 20(4): 439-441.